Entero Therapeutics Beheer

Beheer criteriumcontroles 2/4

De CEO Entero Therapeutics is James Sapirstein, benoemd in Oct2019, heeft een ambtstermijn van 5.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.25M, bestaande uit 41.2% salaris en 58.8% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.75% van de aandelen van het bedrijf, ter waarde $ 16.66K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3.8 jaar en 5.1 jaar.

Belangrijke informatie

James Sapirstein

Algemeen directeur

US$1.2m

Totale compensatie

Percentage CEO-salaris	41.2%
Dienstverband CEO	5.1yrs
Eigendom CEO	0.8%
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	5.1yrs

Recente managementupdates

Recent updates

First Wave BioPharma announces pricing of $6.0 million public offering

Oct 07

First Wave BioPharma extends selloff after announcing strategic shift

Sep 19

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

Sep 07

First Wave BioPharma announces 1-for-30 reverse stock split

Aug 25

First Wave BioPharma to raise capital in convertible preferred stocks offering

Jul 15

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

Oct 19

Analyse CEO-vergoeding

Hoe is James Sapirstein's beloning veranderd ten opzichte van Entero Therapeutics's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$8m
Jun 30 2024	n/a	n/a	-US$10m
Mar 31 2024	n/a	n/a	-US$6m
Dec 31 2023	US$1m	US$514k	-US$16m
Sep 30 2023	n/a	n/a	-US$16m
Jun 30 2023	n/a	n/a	-US$8m
Mar 31 2023	n/a	n/a	-US$9m
Dec 31 2022	US$742k	US$480k	-US$15m
Sep 30 2022	n/a	n/a	-US$22m
Jun 30 2022	n/a	n/a	-US$57m
Mar 31 2022	n/a	n/a	-US$65m
Dec 31 2021	US$1m	US$480k	-US$85m
Sep 30 2021	n/a	n/a	-US$92m
Jun 30 2021	n/a	n/a	-US$74m
Mar 31 2021	n/a	n/a	-US$66m
Dec 31 2020	US$1m	US$463k	-US$42m
Sep 30 2020	n/a	n/a	-US$25m
Jun 30 2020	n/a	n/a	-US$15m
Mar 31 2020	n/a	n/a	-US$16m
Dec 31 2019	US$677k	US$102k	-US$15m

Compensatie versus markt: De totale vergoeding ($USD 1.25M ) James } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).

Compensatie versus inkomsten: De vergoeding van James is gestegen terwijl het bedrijf verliesgevend is.

CEO

James Sapirstein (63 yo)

5.1yrs

Tenure

US$1,245,766

Compensatie

Mr. James R. Sapirstein, R.Ph. M.B.A. has been an Independent Director of ZyVersa Therapeutics, Inc. since January 2023. He served as Interim Chief Executive Officer at Marizyme, Inc. since March 19, 2021...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
James Sapirstein	CEO & Chairman	5.1yrs	US$1.25m	0.75% $ 16.7k
Sarah Romano	Chief Financial Officer	2.7yrs	US$810.56k	0.38% $ 8.4k
Amy Chandler-Skerkis	Vice President of Regulatory Affairs	2.8yrs	geen gegevens	geen gegevens
Martin Krusin	Senior Vice President of Corporate Development	4.8yrs	geen gegevens	geen gegevens
Jennifer Sealey-Voyksner	Senior VP for Research & Development	no data	geen gegevens	geen gegevens

3.8yrs

Gemiddelde duur

56yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ENTO wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
James Sapirstein	CEO & Chairman	5.1yrs	US$1.25m	0.75% $ 16.7k
Alastair Riddell	Independent Director	9.2yrs	US$146.02k	0.000060% $ 1.3
Jack Syage	Director	less than a year	geen gegevens	0.32% $ 7.2k
Edward Borkowski	Lead Independent Director	9.5yrs	US$177.52k	0.00021% $ 4.6
Timothy Ramdeen	Director	less than a year	geen gegevens	geen gegevens

5.1yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ENTO wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.1 jaar).

Entero Therapeutics Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

High number of new and inexperienced directors

First Wave BioPharma, Inc., Annual General Meeting, Aug 25, 2022

First Wave Biopharma, Inc Announces Resignation from the Board of Directors

First Wave BioPharma, Inc. Appoints David Hoffman as Member of the Board

High number of new and inexperienced directors

Recent updates

Less than half of directors are independent

Journey Therapeutics, Inc. entered into a binding term sheet to acquire Entero Therapeutics, Inc. (NasdaqCM:ENTO) in a reverse merger transaction.

Entero Therapeutics Receives Non-Compliance Notice Regarding Nasdaq Listing Rule 5550(a)(2)

Entero Therapeutics Receives Nasdaq Notification Regarding Delayed Form 10-Q

Entero Therapeutics, Inc. announced delayed 10-Q filing

Entero Therapeutics Notifies the Nasdaq Stock Market of its Non-Compliance with Nasdaq Rule 5605(c)(2)

First Wave BioPharma, Inc.(NasdaqGM:ENTO) dropped from NASDAQ Composite Index

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $0.9882 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximately $3 million.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) completed the acquisition of ImmunogenX, LLC for approximator $3 million.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering in the amount of $4.000006 million.

First Wave BioPharma, Inc. has withdrawn its Follow-on Equity Offering.

First Wave BioPharma, Inc. (NasdaqCM:FWBI) signed a non-binding term sheet to acquire ImmunogenX, LLC.

First Wave BioPharma, Inc. has filed a Follow-on Equity Offering.

First Wave Biopharma, Inc. Receives Written Notice from the Listing Qualifications Department of the Nasdaq Stock Market

First Wave BioPharma Receives Notice from Nasdaq Regarding Non-Compliance with Minimum Bid Price Requirement for Continued Listing on The Nasdaq Capital Market

First Wave BioPharma Receives Non-Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Listing Rule 5550(b)(1)

First Wave BioPharma, Inc. Announces Initial Topline Results from Phase 2 Span Clinical Trial Investigating Enhanced Adrulipase Formulation

New major risk - Share price stability

First Wave Biopharma Completes Patient Screening for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

First Wave BioPharma Regains Compliance with Nasdaq’s Minimum Bid Price Requirement

First Wave BioPharma Announces First Patient Screened for Phase 2 SPAN Adrulipase Trial in Cystic Fibrosis

First Wave BioPharma Announces Initiation of Phase 2 Trial Investigating Enhanced Adrulipase Formulation in Exocrine Pancreatic Insufficiency in Patients with Cystic Fibrosis

First Wave BioPharma, Inc. Announces Expansion of Adrulipase Intellectual Property Portfolio

First Wave BioPharma, Inc. Provides Update on IND Filing for Phase 2 Trial of Enhanced Microgranule Formulation of Adrulipase for Exocrine Pancreatic Insufficiency

First Wave BioPharma Receives A Deficiency Notice from the Listing Qualifications Staff of Nasdaq Regarding Minimum Bid Price

First Wave BioPharma, Inc. Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase

First Wave BioPharma, Inc. Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360

First Wave BioPharma, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

First Wave BioPharma announces pricing of $6.0 million public offering

First Wave BioPharma, Inc. Provides Update on Clinical Programs

First Wave BioPharma extends selloff after announcing strategic shift

First Wave BioPharma, Inc. Finalizes Selection of Adrulipase Microgranule Drug Delivery Formulation

First Wave stock slips ~21% on plans for amended FDA application for enzyme adrulipase

First Wave BioPharma Announces Reverse Stock Split

First Wave BioPharma announces 1-for-30 reverse stock split

Price target decreased to US$9.00

High number of new and inexperienced directors

First Wave BioPharma, Inc., Annual General Meeting, Aug 25, 2022

First Wave BioPharma to raise capital in convertible preferred stocks offering

First Wave Biopharma, Inc Announces Resignation from the Board of Directors

First Wave BioPharma, Inc. announced delayed 10-Q filing

First Wave BioPharma, Inc. Appoints David Hoffman as Member of the Board

Price target decreased to US$20.00

High number of new and inexperienced directors

James Pennington Announces His Intention to Retire as Chief Medical Officer of First Wave BioPharma, Inc

First Wave BioPharma, Inc. Files U.S. and PCT Patent Applications for Niclosamide in Long-Haul COVID-19

First Wave Biopharma, Inc. Announce Chief Financial Officer Changes

First Wave BioPharma, Inc. Provides Update on Adrulipase (FW-EPI) Clinical Program

First Wave BioPharma, Inc. Completes Enrollment for Part 2 of RESERVOIR Phase 2 Trial Evaluating FW-COV in COVID-19-Related GI Infections

High number of new directors

First Wave BioPharma Receives A Letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC

First Wave BioPharma Set For New Growth Trajectory With GI Pipeline Expansion De-Risking The Investment

First Wave BioPharma Begins Patient Screening for Phase 2b Clinical Trial Evaluating Niclosamide in Patients with Ulcerative Proctitis and Ulcerative Proctosigmoiditis

Price target decreased to US$25.00

AzurRx BioPharma, Inc. (NasdaqCM:AZRX) agreed to acquire First Wave Bio, Inc. for $230 million.

AzurRx BioPharma, Inc. Announces Positive Results from Independent Data Monitoring Committee Review of Safety Data from Part 1 of RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

AzurRx BioPharma Submits an Investigational New Drug Application for Niclosamide as Treatment for Grade 1 and Grade 2 Immune Checkpoint Inhibitor-Associated Colitis

No longer forecast to breakeven

AzurRx BioPharma, Inc. Announces Positive Topline Data for Phase 2 MS1819 Combination Therapy Trial in Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

AzurRx BioPharma Inc Completes Initial Cohort Enrollment into Part 1 of its RESERVOIR Phase 2 Clinical Trial of Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections

Azurrx Biopharma, Inc. Adds New Clinical Trial Sites in Ukraine for Phase 2 Reservoir Clinical Trial of Niclosamide for the Treatment of Covid-19 Gastrointestinal Infections

AzurRx BioPharma Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market

AzurRx BioPharma, Inc. Doses First Patient in Phase 2 Clinical Trial of Niclosamide for the Treatment of Covid-19 Gastrointestinal Infections

AzurRx Biopharma doses first patient in mid-stage niclosamide COVID-19 study

AzurRx BioPharma, Inc. announced delayed 10-Q filing

AzurRx BioPharma, Inc. Announces Positive Interim Data in Phase 2 Clinical Trial of Ms1819 in Combination with Pert in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

AzurRx BioPharma: An Assessment